Novel approaches to fight Streptococcus pneumoniae

Recent Patents on Anti-Infective Drug Discovery

Volumn 2, Issue 3, 2007, Pages 188-196

  Maestro, Beatriz ^a   Sanz, Jesús M ^a  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Antibiotic resistance; Choline binding proteins; Diagnosis; Enzybiotics; Keratitis; Meningitis; Otitis; Pneumococcus; Pneumonia; Polysaccharidic capsule; Streptococcus pneumoniae; Vaccines

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFDINIR; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DOXYCYCLINE; ERTAPENEM; GARENOXACIN; GEMIFLOXACIN; IMIPENEM; LEVOFLOXACIN; MACROLIDE; MEMBRANE PROTEIN; MOXIFLOXACIN; PENICILLIN G; PENICILLIN G DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOCOCCUS VACCINE; TEBIPENEM PIVOXIL; TETRACYCLINE; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

AGING; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; BACTERIAL VIRULENCE; BACTERIUM IDENTIFICATION; DIAGNOSTIC PROCEDURE; DRUG CHOICE; HUMAN; IMMUNOCOMPROMISED PATIENT; MORTALITY; NONHUMAN; PEDIATRICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; SEROTYPE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 36749044437     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489107782497290     Document Type: Review

References (134)

1. Tuomanen EI, Mitchell TJ, Morrison DA, Spratt BG Eds. The Pneumococcus. ASM Press, Washington, D.C. 2004; 136-47.
2. Tan TQ. Pneumucoccal infections in children. Pediatr Ann 2002; 31: 241-47.
3. WHO. Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Weekly epidemiological record 2007; 82: 93-104.
4. Klugman KP, Madhi SA, Feldman C. HIV and pneumococcal disease. Curr Opin Infect Dis 2007; 20: 11-15.
5. Revai K, McCormick DP, Patel J, et al. Effect of preumococcal conjugate vaccine on nasopharyngeal bacterial colonization during acute otitis media. Pediatrics 2006; 117: 1823-29.
6. Weiser JN. In: The Pneumococcus. Tuomanen El, Mitchell TJ, Morrison DA, Spratt BG Eds. ASM Press, Washington, D.C. 2004; 169-82.
7. Short WR, Tunkel AR. Changing epidemiology of bacterial meningitis in the United States. Curr Infect Dis Rep 2000; 2: 327-31
8. Molyneux E, Walsh A, Phiri A, Molyneux A. Acute bacterial meningitis in children admitted to the Queen Elizabeth Central Hospital, Blantyre, Malawi in 1996-1997. Trop, Med Int Health 1998; 3: 610-18.
9. Kastenbauer S, Pfister H-W. Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases. Brain 2003; 126: 1015-25.
10. Garibaldi RA. Epidemiology of communit-acquired respiratory tract infections in adults: incidence, aetiology and impact. Am J Med 1985; 78: 32S-38S.
11. Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2002; 2: 25-32.
12. Fadson DS, Scott J. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine 1999; 17: s11-18.
13. Garau J. Role of β-lactam agents in the treatment of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005; 24: 83-99.
14. Alho OP, Koivu M, Sorri M, Rantakallio P. The occurrence of acute otitis media in infants: a life-table analysis. Int J Pediatr Otorhinolaryngol 1991; 21: 7-14.
15. Mufson MA. In: Mandell GL, Douglas R, Benett JE Eds. Principle and Practice of Infectious Diseases. Churchill Levinstone, N.Y. 1990; 1539-50.
16. Cripps AW, Otczyk DC, Kyd JM. Bacterial otitis media: a vaccine preventable disease?. Vaccine 2005; 23: 2304-310.
17. Gonzales R, Malone DC, Maselli JH, Sande MA. Excessive antibiotic use for acute respiratory infections in the United States. Clin Infect Dis 2001; 33: 757-62.
18. Giebink G. Otitis media: the chinchilla model. Microb Drug Resist 1999; 5: 57-72.
19. Berman S. Otitis media in developing countries. Pediatrics 1995; 96:126-31.
20. Yu VL, Chien CC, Feldman C, et al. An international prospective study of pneumococcal bacteraemia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37: 230-37.
21. Parmar P, Salman A, Kalavathy CM, Jesudasan CA, Thomas PA. Pneumucoccal keratitis: a clinical profile. Clin Experiment Ophthalmol 2003; 31: 44-47.
22. Brook I. Bacteriology of acute and chronic ethmoid sinusitis. J Clin Microbiol 2005; 43: 3479-80.
23. Bradley JS, Kaplan SL, Tan TQ, et al. Pediatric pneumococcal bone and joint infections. Pediatrics 1998; 102: 1376-82.
24. Lund E, Henrichsen J. Laboratory diagnosis, serology and epidemiology of Streptococcus pneumoniae. Methods Microbiol 1978; 12: 241-62.
25. Henney JE. Quick test for pneumonia. JAMA 1999; 282: 1218.
26. Murdoch DR, Laing It, Mills GD, et al. Evaluation of a rapid immonochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol 2001; 39: 3495-98.
27. Domínguez J, Gali S, Blanco S, et al. Detection of Streptococcus pneumoniae antigen by a rapid immunochromatographic assay in urine samples. Chest 2001; 119: 243-49.
28. Navarro D, García-Maset L, Gimeno C, et al. Performance of the Binax NOW Streptococcus pneumoniae urinary antigen assay for diagnosis of pneumonia in children with underlying pulmonary diseases in the absence of acute pneumococcal infection. J Clin Nficrobiol 2004; 42: 4853-55.
29. Marcos MA, Martínez E, Almela M, Mensa J, Jiménez de Anta MT. New rapid antigen test for diagnosis of pneumococcal meningitis. Lancet 2001; 357: 1499-500.
30. Millar BC, Moore JE. Molecular diagnostics: current options. Methods Mol Biol 2004; 266: 139-66.
31. Saunders NA. Real-time PCR. Methods Mol Biol 2004; 266: 191-211.
32. Carvalho MGS, Tondella ML, McCaustland K, et al. Evaluation and improvement of real-time PCR detection assays to lyt 4, ply and psa.4 genes for detection of pneumococcal DNA. J Clin Microbiol 2007 doi: 10.1128/JCM.02498-06, in press.
33. Toikka P, Nikkari S, Ruuskanen O, Leinonen M, Mertsola J. Pneumolysin PCR-based diagnostics of invasive pneumococcal infection in children. J Clin Microbiol 1999; 37: 633-37.
34. Kanclerski K, Mollby R. Production and purification of Streptococcus pneumoniae hemolysin (pneumolysin). J Clin Microbiol 1987; 25: 222-25.
35. Curless CE, Guiver M, Borrow R, Edwards-Jones V, Fox AJ, Kaczmarski EB. Simultaneous detection of Neisseria meningitidis, Haemophilus influenzae and Streplococcus pneumoniae in suspected cases of meningitis and septicemia using real-time PCR. J Clin Microbiol 2001; 39: 1553-58.
36. van Gastel EV, Bruyneels P, Verstreprn W, Mertens A. Evaluation of a real-time polymerase chain reaction assay for the diagnosis of pneumococcal and meningococcal meningitis in a tertiary care hospital. Eur J Clin Microbiol Infect Dis 2007, doi 10.1007/s 10096-007-0350-0, in press.
37. Russell H, Tharpe JA, Wells DE, White EG, Johnson JE. Monoclonal antibody recognizing a species-specific protein from Streptococcus pneumoniae. J Clin Microbiol 1990; 28: 2191-95.
38. Crook J, Tharpe JA, Johnson SE, et al. Immunoreactivity of five monoclonal antibodies against the 37-kilodalton common cell wall protein (PsaA) of Streptococcus pneumoniae. Clin Diagn Lab Immunol 1998; 5: 205-10.
39. Jado I, Fenoll A, Casal J, Pérez A. Identification of the psaA gene, coding for pneumococcal surface adhesin A, in viridans group streptococci other than Streptococcus pneumoniae. Clin Diagn Lab Immunol 2001; 8: 895-98.
40. Morrison KE, Lake DL, Crook J, et al. Confirmation of psaA in all 90 serotypes of Streptococcus pneumoniae by PCR and potential of this assay for identification in diagnosis. J Clin Microbiol 2000; 38: 434-37.
41. Sampson, J.S., Morrison, K.E., Whitmon, J.C., Ades, E., Carlone, G.M.: US20056869767 (2005).
42. McAvin JC, Reilly, PA, Roudabush RM, et al. Sensitive and specific method for rapid identification of Streptococcus pneumoniae using real-time fluorescence PCR. J Clin Microbiol 2001; 39: 3446-51.
43. Sheppard CL, Harrison TG, Morris I, Hogan A, George RC. Autolysin-targeted Light Cycler assay including internal process control for detection of Streptococcus pneumoniae DNA in clinical samples. J Med Microbiol 2004; 53: 189-95.
44. Seki, M., Tsuda, H.: W006043368 (2006).
45. López R, García E. Recent trends on the molecular biology of pneumococcal capsules, lytic enzymes and bacteriophage. FEMS Microbiol Rev 2004; 28: 553-80.
46. Messmer TO, Sampson JS, Stinson A, Wong B, Carlone GM, Facklam RR. Comparison of four polymerase chain reaction assays for specificity in the identification of Streplococcus pneumoniae. Diagn Microbiol Infect Dis 2004; 49: 249-54.
47. Llull D, López R, García E. Characteristic signatures of the lytA gene provide a basis for rapid and reliable diagnosis of Streptococcus pneumoniae infections. J Clin Microbiol 2006; 44: 1250-56.
48. O'Neill AM, Gillespie SH, Whiting GC. Detection of penicillin susceptibility in Streptococcus pneumoniae by pbp2b PCR-restriction fragment length polymorphism analysis. J Clin Microbiol 1999; 37: 157-60.
49. Hakenbeck, R.: US2004146886 (2004).
50. Kawamura Y, Whiley RA, Shu SE, Ezaki T, Hardie JM. Genetic approaches to the identification of the milis group within the genus Streptococcus. Microbiology 1999; 145: 2605-13.
51. Sharpe BA, Flanders SA. Community-acquired pneumonia: a practical approach to management for the hospitalist. J Hosp Med 2006; 1: 177-90.
52. Mandell LA, Barlett JG, Dowell SF, File TM, Mosher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-33.
53. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39: 1267-84.
54. Powers JH. Diagnosis and treatment of acute otitis media: evaluating the evidence. Infect Dis Clin North Am 2007; 21: 409-26.
55. Ferrara AM. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance. Infection 2005; 33: 106-14.
56. Jones RN, Sader HS, Stilwell MG, Fritsche TR. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-Tesistant Streplococcus pneumoniae. Diagn Microbiol Infect Dis 2007; 58: 1-7.
57. Bast, D., Davidson, R.J., DeAzavedo, J., Low, D.E.: US2004147527 ( 2004)
58. Kaplan SL, Mason EO Jr. Management of infections due to antibiotic-resistant Streplococcus pneumoniae. Clin Microbiol Rev 1998; 11: 628-44.
59. Yogev R, Guzman-Cottrill J. Bacterial meningitis in children: critical review of current concepts. Drugs 2005; 65: 1097-112.
60. Wexler HM. In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother. 2004; 53(Suppl S2): ii11 -ii21.
61. Jones RN, Sader HS, Stilwell MG, Fritschc TR. Garenoxacin activity against isolates from patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2007; 58: 1-7.
62. Swainston-Harrison T, Keam SJ. Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US. Drugs 2007; 67: 773-92.
63. Sharpe BA, Flanders SA. Community-acquired pneumonia: a practical approach to management for the hospitalist. J Hosp Med 2006; 1: 177-90.
64. American Academy of Pediatrics (AAP) and American Academy of Family Physicians (AAFP) subcommitee on Management of Acute Otitis Media. Diagnosis and management of acute otitis media. Pediatrics 2004; 113: 1451-65.
65. Segal N, Leibovitz E, Dagan I, Leiberman A. Acute otitis media - diagnosis and treatment in the era of antibiotic resitant organisms: updated clinical practice guidelines. Int J Pediatr Otorhinolaryngol 2005; 69: 1311-19.
66. Hotomi M, Suzumoto M, Itahashi K, et al. Efficacy of a novel oral carbapenem, tebipenem pivoxil (TBM-PI), against experimental otitis media caused by penicillin resistant Streptococcus pneumoniae in chinchilla. Vaccine 2007; 25: 2478-84.
67. Rosenfeld RM, Vertrees JE, Carr J, et al. Clinical efficacy of antimicrobial drugs for acute otitis media: metaanalysis of 5400 children from thirty-three randomized trials. J Pediatr 1994; 124: 355-67.
68. Glasziou PP, Del Mar CB, Sanders SL, Hayem M. Antibiotics for acute ofitis media in children. Cochrane Database Syst Rev 2004; 1: CD000219.
69. Wong T, Ormonde S, Gamble G, McGhee CN. Severe infective keratitis leading to hospital admission in New Zealand. Br J Ophthalmol 2003; 87: 1103-108.
70. Liesegang TJ. Bacterial Keratitis. In: Kaufman HE, Barron BA, McDonald MB (eds), The Cornes, Butterworth-Heinemann, Boston, 1998; 159-218.
71. Cutarelli PE, Lazarus HM, Jacobs MR, Lass JH. Antimicrobial activity and in vitro corneal epithelial toxicity of antimicrobial agents for gram-positive corneal pathogens. Curr Eye Res 1993; 12: 603-608.
72. Marquart, M.E., O'Callaghan, R.J.: US2006229283 (2006).
73. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343: 1917-24.
74. Fogarty C, Torres A, Choudhri S, Herrington J, Ambler J. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia. Int J Clin Pract 2005; 59: 1253-59.
75. Cartwright K. Pneumococcal disease in western Europe: burden of disease, antibiotic resistance and management. Eur J Pediatr 2002; 161: 188-95.
76. Craig WA. Overview of newer antimicrobial formulations for overcoming pneumococcal resistance. Am J Med 2004; 117(suppl 3A): 16S-22S.
77. Bax, R.P.: US20016214359 (2001).
78. Hakenbeck R, Grebe T, Zahner D, Stock JB. β-Lactam resistance in Streptococcus pneumoniae: penicillin-binding proteins and non-penicillin-binding proteins. Mol Microbiol 1999; 33: 673-78.
79. Goffin C, Ghuysen JM. Multimodular penicillin-binding proteins: an enigmatic family of orthologs and paralogs. Microbiol Mol Biol Rev 1998; 62: 1079-93.
80. Filipe SR, Pinho MG, Tomasz A. Characterization of the murMN operon involved in the synthesis of branched peptidoglycan peptides in Streptococcus pneumoniae. J Biol Chem 2000; 275: 27768-74.
81. Filipe SR, Tomasz A. Inhibition of the expression of penicillin resistance in Streptococcus pneumoniae by inactivation of cell wall muropeptide branching genes. Proc Natl Acad Sci USA 2000; 97: 4891-96.
82. Tomasz, A., Filipe, S.R.: US2005165224 (2005).
83. Felmingham D, Cantón R, Jenkins SG. Regional trends in β-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004. J Infect 2007; 55: 111-118.
84. Jacobs MR, Felmingham D, Applebaum PC, Grüneberg RN. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229-46.
85. McGee L, Goldsmith CE, Klugman K. Fluoroquinolone resistance among clinical isolates of Streplococcus pneumoniae belonging to international multiresistant clones. J Antimicrob Chemother 2002; 49: 173-76.
86. Dias I, Louro D, Canica M. Antimicrobial susceptibility of invasive Streptococcus pneumoniae isotates in Portugal over an 11-year period. Antimicrob Agents Chemother 2006; 50: 2098-105.
87. Rossi F, Andreazzi D. Overview of tigecycline and its role in the era of antibiotic resistance. Braz J Infect Dis 2006; 10: 203-16.
88. Testa, R.T., Calhoun, J., Mader, J.T., Mader, D.: US2005148553 (2005).
89. Heerbeek N, Straetemans M, Wiertsema SP, et al. Effect of combined pneumococcal conjugate and polysaccharide vaccination on recurrent otitis media with effusion. Pediatrics 2006; 117: 603-608.
90. Laferriere, C.A.J., Poolman, J.: US2006051361 (2006).
91. O'Hagan, D.: US2006147466 (2006).
92. Hausdorff W, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005; 5: 83-93.
93. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344: 403-409.
94. Darkes MJ, Plosker GL. Pneumococcal conjugate vaccine (Prevnar; PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection. Paediatr Drugs 2002; 4: 609-30.
95. Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 2004; 113: 443-49.
96. Byington CL, Samore MH, Stoddard GJ, et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin Infect Dis 2005; 41: 21-29.
97. Nesin M, Ramirez M, Tomasz A. Capsular transformation of multidrug-resistant Streptococcus pneumoniae in vivo. J Infect Dis 1998; 177: 707-713.
98. Beutels P, Thiry N, Damme PV. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination- a review (2002-2006). Vaccine 2007; 25: 1355-67.
99. Hausdorff, W.P., Siber, G.R., Paradiso, P.R.: WO06110391 (2006).
100. Hausdorff WP, Yothers G, Dagan R, et al. Multinational study of pneumococcal serotypes causing acute otifis media in children. Pediatr Infect Dis J 2002; 21: 1008-16.
101. Jonsdottir, I.: US2006140981 (2006).
102. Gosink KK, Mann E, Guglielmo C, Tuomanen El, Masure HR. Role of novel choline binding proteins in virulence of Streptococcus pneumoniae, Infect Immun 2000; 69: 5690-95.
103. López R, García E, García P, García JL. In: The Pneumocaccus (Tuomanen EI, Mitchell TJ, Morrison D, Spratt BG eds). ASM Press, 2004; 75-88.
104. Bogaert D, Hermans PWM, Adrian PV, Rümke HC, de Groot R. Pneumococcal vaccines: an update on current strategies. Vaccine 2004; 22: 2209-20.
105. McDaniel LS, Sheffield IS, Delucchi P, Briles DE. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect Immun 1991; 59: 222-28.
106. Ren B, Szalai AJ, Thomas O, Hollingshead SK, Briles DE. Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae. Infect Immun 2003; 71: 75-85.
107. Moore QC, Bosarge JR, Quin LF, McDaniel LS. Enhanced protective immunity against pneumococcal infection with PspA DNA and protein. Vaccine 2006, 24; 5755-61.
108. Briles, D.E., Yother, J.L., McDaniel, L.S.: EP0622081 (2002).
109. White P, Hermansson A, Svanborg C, Briles D, Prellner K. Effects of active immunization with a pneumococcal surface protein (PspA) and of locally applied antibodies in experimental otitis media. ORL J Otorhinolaryngol Relat Spec 1999; 61: 206-11.
110. Wizemann, T.M., Koenig, S., Johnson, L.S.: WO9951266 (1999).
111. Wu HY, Nahm MH, Guo Y, Rusell MW, Briles DE. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis 1997; 175: 839-46.
112. Briles DE, Hollingshead SK, King J, et al. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 2000; 182: 1694-701.
113. D'Ambra, A.J., Arnold, F.J., Maleckar, J.R., McMaster, R.P.: US20030035806 (2003).
114. Briles, D.E., Hollingshead, S.K., Brooks-Walter, A.: US2005196405 (2005).
115. Masure, H. R., Rosenow, C.I., Tuomanen, E., Wizemann, T.M.: US2005048590 (2005).
116. Masure, H. R., Rosenow, C.I., Tuomanen, E., Wizemann, T.M.: US20030175293 (2003).
117. Wizemann, T.M., Johnson, L., Koenig, S.: NZ507717 (2004).
118. Seo J-Y, Seong SY, Ahn B-Y, Kwon IC, Chung H, Jeong SY. Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin A encapsulated in microspheres. Infect Immun 2002; 70: 1143-49.
119. Huebner, R.C., Sampson, J.S., Carlone, G.M., Ades, E., Briles, D.E.: WO000076541 (2000).
120. García-Suárez MM, Vázqucz F, Méndez FJ. Streptococcus pneumoniae virulence factors and their clinical impact: an update, Enferm Infecc Microbiol Clin 2006; 24: 512-17.
121. Briese T, Hakenbeck R. Interaction of the pneumococcal amidase with lipoteichoic acid and choline. Eur J Biochem 1985; 146: 417-27.
122. Fernández-Tornero C, García E, Pascual-Teresa B, López R, Giménez-Gallego G, Romero A. Ofloxacin-like antibiotics inhibit pneumococcal cell wall-degrading virulence factors. J Biol Chem 2005; 280: 19948-57.
123. Maestro B, González A, García P, Sanz JM. Inhibition of pneumococcal choline-binding proteins and cell growth by esters of bicyclic amines. FEBS J 2007; 274: 364-76.
124. Llull D, Rivas L, García, E. in vitro Bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic Streptococci. Antimicrob Agents Chemother 2007; 51: 1844-48.
125. Kharat AS, Tomasz A. Drastic reduction in the virulence of Streptococcus pneumoniae expressing type 2 capsular polysaccharide but lacking choline residues in the cell wall. Mol Microbiol 2006; 60: 93-107.
126. Weiser, J.N.: WO9812346 (1998).
127. Espinosa, A., Lacal, J.C., Gallo, M.A., Campos, J.M.: WO9805644 (1998).
128. Lacal, J.C.: ES2148092 (2000).
129. Nelson D, Loomis L, Fischetti VA. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci USA 2001; 98: 4107-12.
130. Loeffler JM, Nelson D, Fischetti VA. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 2001; 294: 2170-72.
131. Loeffler JM, Djurkovic S, Fischetti VA. Phage lytic enzyme Cp1-1 as a novel antimicrobial for pneumococcal bacteremia. Infect Immun 2003; 71: 6199-204.
132. Jado I, López R, García E, Fenoll A, Casal J, Garcia P. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J Antimicrob Chemother 2003; 52: 967-73.
133. Fischetti, V.A.: US20060159671 (2006).
134. McCullers JA, Karlström A, Iverson A, Loeffler JM, Fischetti VA. Novel strategy to prevent otitis media caused by colonizing Streptococcus pneumoniae. PloS Pathog 2007; 3: e28. doi:10.1371/ journal.ppat.0030028.